NCT05184179View on ClinicalTrials.gov

Observational Study to Evaluate the Therapeutic Effectiveness and Safety of Olomax Tab

CompletedOBSERVATIONAL
Enrollment

5,450

Participants

Timeline

Start Date

December 1, 2019

Primary Completion Date

August 16, 2022

Study Completion Date

August 16, 2022

Conditions
HypertensionDyslipidemia
Interventions
DRUG

Olmesartan Medoxomil

Olmesartan Medoxomil, Amoldipine Besylate, Rosuvastatin Ca

Trial Locations (1)

18450

Hallym University Dongtan Sacred Heart Hospital, Hwaseong-si

Sponsors
All Listed Sponsors
lead

Daewoong Pharmaceutical Co. LTD.

INDUSTRY

NCT05184179 - Observational Study to Evaluate the Therapeutic Effectiveness and Safety of Olomax Tab | Biotech Hunter | Biotech Hunter